medRxiv preprint doi: https://doi.org/10.1101/2022.03.26.22272972; this version posted March 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

1 Damaging missense variants in *IGF1R* implicate a role for IGF-1 resistance in the 2 aetiology of type 2 diabetes

- 3
- 4 Eugene J. Gardner^{@,1}, Katherine A. Kentistou¹, Stasa Stankovic¹, Samuel Lockhart², Eleanor
- 5 Wheeler¹, Felix R. Day¹, Nicola D. Kerrison¹, Nicholas J. Wareham¹, Claudia Langenberg^{1,4},
- Stephen O'Rahilly^{*,2,3}, Ken K. Ong^{*,1,5}, John R. B. Perry^{*,@,1,6} 6
- 7
- 8 ¹MRC Epidemiology Unit, Wellcome–MRC Institute of Metabolic Science, University of Cambridge, 9 Cambridge, UK
- 10 ²MRC Metabolic Diseases Unit, Wellcome–MRC Institute of Metabolic Science, University of
- 11 Cambridge, Cambridge, UK
- 12 ³NIHR Cambridge Biomedical Research Centre, Cambridge, UK
- 13 ⁴Computational Medicine, Berlin Institute of Health at Charité–Universitätsmedizin Berlin, Berlin,
- 14 Germany
- 15 ⁵Department of Paediatrics, University of Cambridge, Cambridge, UK
- 16 ⁶Metabolic Research Laboratory, Wellcome–MRC Institute of Metabolic Science, University of
- 17 Cambridge, Cambridge, UK
- 18
- 19 * These authors jointly supervised this work
- 20 [@] Corresponding authors: eugene.gardner@mrc-epid.cam.ac.uk; john.perry@mrc-
- 21 epid.cam.ac.uk

Abstract 22

23 Type 2 diabetes (T2D) is a chronic metabolic disorder with a significant genetic component.

- 24 While large-scale population studies have identified hundreds of common genetic variants
- 25 associated with T2D susceptibility, the role of rare (minor allele frequency < 0.1%) protein
- 26 coding variation is less clear. To this end, we performed a gene burden analysis of 18,691
- 27 genes in 418,436 (n=32,374 T2D cases) individuals sequenced by the UK Biobank (UKBB)
- 28 study to assess the impact of rare genetic variants on T2D risk. Our analysis identified T2D
- 29 associations at exome-wide significance ($P < 6.9 \times 10^{-7}$) with rare, damaging variants within 30 previously identified genes including GCK, GIGYF1, HNF1A, and TNRC6B. In addition,
- 31 individuals with rare, damaging missense variants in the genes ZEB2 (N=31 carriers;
- 32 OR=5.5 [95% CI=2.5-12.0]; p=6.4x10⁻⁷). MLXIPL (N=245; OR=2.3 [1.6-3.2]; p=3.2x10⁻⁷), and
- IGF1R (N=394; OR=2.4 [1.8-3.2]; p=1.3x10⁻¹⁰) have higher risk of T2D. Carriers of damaging 33
- missense variants within *IGF1R* were also shorter (-2.2cm [-1.8-2.7]; p=1.2x10⁻¹⁹) and had 34
- higher circulating protein levels of insulin-like growth factor-1 (IGF-1; 2.3 nmol/L [1.7-2.9] 35
- p=2.8x10⁻¹⁴), indicating relative IGF-1 resistance. A likely causal role of IGF-1 resistance on 36
- 37 T2D was further supported by Mendelian randomisation analyses using common variants.
- 38 Our results increase our understanding of the genetic architecture of T2D and highlight a
- 39 potential therapeutic benefit of targeting the Growth Hormone/IGF-1 axis.

Introduction 40

41 Type 2 diabetes (T2D) is a complex disease characterised by insulin resistance and beta-

- 42 cell dysfunction. An estimated 630 million adults are expected to have T2D by 2045¹ making
- 43 it one rol the fastest growing global health challenges of the 21st century see an one wide ractice.

association studies (GWAS) have successfully identified more than 500 genomic loci to be
 associated with T2D², although the majority of these are driven by common variants with
 small individual effects on T2D risk.

47

48 Over 90% of GWAS loci lie in non-coding regions of the genome³, presenting a major hurdle for the identification of the underlying causal genes and the translation of these findings into 49 50 mechanistic insight. In contrast, analysis of rare protein-coding variation captured by DNA 51 sequencing has the potential to more directly implicate individual genes and biological 52 mechanisms. The UK Biobank (UKBB)⁴ study recently made Exome Sequencing (ES) data available for 454,787 UKBB participants⁵. This offers an unprecedented opportunity to 53 explore the contribution of rare coding variation to the risk of T2D with much greater power 54 than previously possible⁶⁻⁸. Initial exome-wide association analyses of these data have 55 56 identified gene-based associations with increased risk of T2D for GCK, HNF1A, HNF4A, 57 GIGYF1, CCAR2, TNRC6B and PAM, and protective effects for variants in FAM234A and MAP3K15^{5,9-14}. 58

59

In this study, we combined multiple sources of health record data to identify additional T2D

61 cases and used an extended range of variant classes and allele frequency cutoffs in order to

62 directly implicate novel genes in the aetiology of T2D. Our results highlight a number of

63 previously missed associations and support a role for Insulin-like Growth Factor 1 (IGF-1)

64 resistance in the pathogenesis of T2D.

65 Results

66 Exome-wide burden testing in the UK Biobank

To identify genes associated with T2D risk, we performed an Exome-wide association study

68 (ExWAS) using ES data derived from 418,436 European genetic-ancestry UKBB

69 participants⁵. As our primary outcome, we identified 32,374 (7.7%) participants with likely

incident or prevalent T2D using phenotype curation that integrated multiple data sources,

including hospital episode statistics, self-reported conditions, death records, and use of T2D
 medication (see methods).

73

74 Individual gene burden tests were performed by collapsing genetic variants across 18,691

75 protein-coding genes in the human genome. We tested four functional categories across two

population prevalences (minor allele frequency < 0.1% and singletons), including high-

confidence Protein Truncating Variants (PTVs), missense variants stratified by two REVEL
 score thresholds¹⁵, and synonymous variants as a negative control (Figure 1; methods). We

79 identified 13 gene-functional annotation pairs with 30 or more rare allele carriers,

80 representing 7 non-redundant genes, associated with T2D at exome-wide statistical

81 significance ($p < 6.9 \times 10^{-7}$; Supplementary Table 1; methods). Our results are statistically

82 well-calibrated, both as indicated by low exome-wide inflation scores (e.g. PTV λ =1.047) and

83 by the absence of significant associations with synonymous variant burden (Figure 1B-E;

84 Supplementary Figure 1). To ensure our results were not biassed by our approach, we

85 implemented burden tests using STAAR¹⁶ and a logistic model and arrived at substantially

similar conclusions (Supplementary Figure 2; Supplementary Table 1; methods).



88 Figure 1. Exome-wide association results for T2D. (A) Manhattan plot displaying results of gene 89 burden tests for T2D risk. Genes passing exome-wide significance ($p < 6.9 \times 10^{-7}$) are labelled. Point 90 shape indicates variant class tested. (B-E) QQ plots for (B) high confidence PTVs (C) REVEL ≥ 0.5 91 Missense Variants (D) REVEL \geq 0.7 missense variants and (E) synonymous variants (negative 92 control).

93

94 We confirmed the T2D associations at all three genes identified by three previous studies of T2D risk that incorporated European genetic-ancestry individuals from the UKBB 95 study^{11,12,14}: GCK (N=35 carriers; OR=58.5 [95% CI=25.5-134.5]; p=2.0x10⁻⁵⁸), HNF1A 96

(N=33; OR=12.7 [6.2-25.8]; p=4.4x10⁻²⁰), and GIGYF1 (N=133; OR=4.7 [3.1-7.0]; p=4.4x10⁻²⁰) 97

¹⁶; Figure 2). As in these previous studies, we similarly found that carriers of PTVs within 98

these genes had substantially increased risk for developing T2D (Figure 1A). 99

100

101 We also confirmed the T2D association at TNRC6B (N=35; OR=10.5 [5.3-21.0]; p=1.4x10⁻

102 ¹⁴), which was previously reported as 'potentially spuriously associated' with T2D risk¹¹;

103 several new lines of evidence provide confidence in this association. Firstly, our result is not

104 attributable to a single variant of large effect as evidenced by the strength of association with

- singleton variants (Figure 1A). Secondly, aside from a single individual carrying two 105 balanced deletions, inspection of the underlying ES reads did not reveal a markedly
- 106 107 increased error rate in variant calling or genotyping in TNRC6B as was suggested by Deaton
- et al.¹¹. Thirdly, the association persisted after excluding 14 individuals who carry a singleton 108
- PTV in a potentially non-constitutive exon as measured by PEXT ($p=3.6x10^{-7}$)¹⁷. Finally, we 109
- 110 also found that TNRC6B PTV carriers had elevated HbA1c levels when considering both
- T2D cases (4.1 mmol/mol [2.5-5.7]; $p=7.2x10^{-7}$; Supplementary Figure 3) and controls (1.6 111
- mmol/mol [0.2-2.1]; p=1.8x10⁻²), consistent with the elevated long-term blood glucose levels 112
- 113 observed in T2D patients.
- 114
- 115 We also identified three additional genes that, when disrupted by rare genetic variation
- (minor allele frequency < 0.1% or singletons), are associated with increased T2D risk: 116
- *IGF1R* (N=394; OR=2.4 [1.8-3.2]; p=1.3x10⁻¹⁰), *MLXIPL* (N=245; OR=2.3 [1.6-3.2]: 117
- p=3.2x10⁻⁷), and ZEB2 (N=31; OR=5.5 [2.5-12.0]; p=6.4x10⁻⁷; Figure 1). Unlike previously 118
- 119 reported genes outlined above, damaging missense variants but not PTVs in these genes

- 120 were associated with T2D risk (Figure 2). Indeed, at these genes T2D associations were
- 121 apparent only with missense variants with high REVEL scores (≥ 0.7), or those variants

122 considered to be the most damaging as per current (2020) Association for Clinical Genomic

- 123 Science guidelines.
- 124



125

126 Figure 2. Relationship between cumulative minor allele frequency and odds ratio for T2D.

127 Plotted is T2D risk as quantified by log(Odds Ratio) versus cumulative minor allele frequencies 128 (cMAF) for genes significantly associated with T2D risk. For each gene, only the most significantly

129 associated variant mask is shown. Error bars indicate 95% confidence intervals.

130

131 Specifically, and as expected, we found that carriers of PTVs within GCK, GIGYF1, and

HNF1A all had significantly elevated circulating glucose and HbA1c levels. Among novel 132

133 genes, IGF1R missense carriers had nominally higher HbA1c levels (1.1 mmol/mol [0.6-1.6];

134 $p=3.7x10^{-6}$).

Exploring Common Variant Associations at Highlighted Genes 135

136 We next attempted to cross-validate the rare-variant associations for all seven exome-wide significant genes by identifying proximal common variants (±50kb of a gene's coding 137 138 sequence) previously reported to be associated with related glycaemic or metabolic 139 phenotypes (methods; Supplementary Table 2). Four genes fell within glycaemic trait 140 associated loci and all seven overlapped known metabolic trait associations. For several of 141 these common variant-phenotype combinations, we also identified an association with rare 142 variant burden (Supplementary Figure 3). Additionally, three of the four novel genes we

- report here were identified in the most recent publicly available T2D GWAS² as being either 143
- 144 the closest or most likely causal gene for a common variant genome-wide significant signal:
- 145 IGF1R, TNRC6B, and ZEB2 (Supplementary Table 2).
- 146

147 Notably, common non-coding variants at the IGF1R locus have been previously reported for T2D and fasting glucose^{2,18}. The lead fasting glucose-associated SNP (rs6598541-A; p= 148

4x10⁻¹²) was associated with 0.0114 mmol/L [0.0097-0.0131] higher levels of glucose, while 149

- the lead T2D SNP (rs59646751-T; p=4x10⁻⁹) increases risk of T2D by an odds ratio of 1.024 150
- [1.020-1.028]. Both SNPs are intronic in *IGF1R*, in moderate LD in European populations 151
- (R²=75.5%)¹⁹, and are eQTLs for *IGF1R*²⁰. Furthermore, at both SNPs the *IGF1R* 152
- 153 expression-lowering alleles are associated with higher levels of circulating IGF-1 ($p=7x10^{-7}$
- 154 and $9x10^{-7}$, respectively; Figure 3)²¹ and with higher T2D risk and fasting glucose.



155

156 Figure 3. Common variant associations at the IGF1R locus. Association pattern between SNPs at 157 the IGF1R locus and Fasting Glucose levels (A) and IGF-1 levels (B).

Interrogating IGF1R and Risk for T2D 158

To understand how rare damaging missense variants in IGF1R lead to increased risk of 159 160 T2D, we performed burden tests for circulating IGF-1 levels and anthropometric traits. We found that carriers of damaging missense variants in IGF1R had increased circulating IGF-1 161 162 levels (2.1 nmol/L [1.5-2.6]; p=1.9x10⁻¹⁴), but shorter adult stature (-2.2cm [-1.8-2.7]; 163 $p=1.2x10^{-19}$), and lower relative height at age 10 ($p=1.1x10^{-7}$). These findings indicate that 164 carriers of rare damaging missense variants in *IGF1R* that increase risk of T2D have relative 165 IGF-1 resistance.

- 166
- To explore how damaging missense variants disrupt *IGF1R* function, we next categorised 167 variants by protein domain. Carriers of qualifying variants within the IGF1R protein kinase 168 $(residues 999-1274)^{22}$ had a higher risk for T2D (N= 179; OR=3.4 [2.3-4.9]; p=1.9x10⁻¹⁰) than 169 170 those with qualifying variants outside this domain (N=215; OR=1.7 [1.2-2.6]; p=8.2x10⁻³). We 171 thus conclude that dysfunction within the protein kinase domain could decrease downstream 172 signal transduction resulting in IGF-1 resistance. This may also explain why, despite the 173 relatively large number of *IGF1R* (N=64) PTV carriers in the UKBB, we did not find that 174 IGF1R PTV carriers had increased T2D risk. When bound by IGF-1 and to induce 175 downstream signal transduction, IGF1R functions as a homo or heterodimer (i.e. with INSR as a hybrid receptor)²³. As half of a missense carrier's *IGF1R* molecules will contain errors in 176 177 the protein kinase domain, dimerisation will incorporate at least one defective molecule 75% 178 of the time and therefore lead to reduced downstream signal transduction. In the case of 179 PTV carriers, since one copy is likely missing due to nonsense-mediated decay, dimerisation 180 will always incorporate two functional copies. Therefore, the association of damaging IGF1R 181 missense variants with T2D may be due to a dominant-negative effect rather than decreased 182 protein abundance; however, additional functional studies are ultimately required to confirm the mechanism underlying these variants. 183

184 To explore whether rare variants in other components of the GH-IGF1 hormone pathway might influence T2D risk, we next identified a further nine genes in the GH-IGF1 pathway 185 186 that showed gene-burden associations with circulating IGF-1 levels in any of our burden 187 tests (Supplementary Table 3), including seven genes with known roles in regulating GH secretion or GH signalling and three genes with known roles in IGF-1 bioavailability. We 188 189 tested their associations with childhood and adult height to indicate the functional relevance 190 of rare variation in these genes. None of the seven GH-related genes showed any 191 association with T2D. Rare damaging variants in IGFALS, which encodes a component of 192 the IGF-1 ternary complex, lowered lower circulating IGF-1 and were nominally associated 193 with shorter childhood height (indicative of lower IGF-1 bioactivity) and higher risk of T2D. 194 Rare damaging variants in IGFBP3 (the major IGF binding protein), which lowered 195 circulating IGF-1 levels, were nominally associated with taller childhood height (indicative of higher IGF-1 bioactivity) and lower risk of T2D. Hence damaging rare variants that disrupt 196 197 IGF-1 bioactivity, but not those that alter GH secretion or signalling, appear to increase T2D 198 risk.

199 Causality of IGF-1 Levels with T2D Risk

A previous epidemiological study described a protective association between baseline circulating IGF-1 protein levels and incident T2D²⁴. However, subsequent similar studies found no such association^{25,26} and conversely a previous study that modelled common genetic variants in a Mendelian randomization framework inferred an adverse causal effect of higher circulating IGF-1 levels on T2D²⁷.

204

To explore this apparent inconsistency, we examined the likely causal role of IGF-1 on T2D 206 207 by modelling 784 independent genetic signals for circulating IGF-1 levels identified in 428,525 white European UKBB individuals²¹ and summary statistics from the largest 208 reported GWAS meta-analysis of T2D²⁸. We confirmed the previously reported²⁷ association 209 between genetically-predicted higher IGF-1 levels and higher risk of T2D in inverse-variance 210 weighted (IVW; OR=1.105 per SD [95% CI 1.039-1.170]; p=2.9x10⁻³) and sensitivity models 211 212 (Supplementary Table 4). However, we noted substantial heterogeneity in the relationships 213 between individual IGF-1 signals and T2D (I-square=85.7%) as well as in their associations with adult height (IVW Beta=0.142; p=8.9x10⁻⁹; I-square=97.7%). Among the common 214 genetic instruments for higher circulating IGF-1 levels, individual variants at the IGF1 locus 215 216 (rs11111274) and the IGF1R locus (rs1815009) show directionally-opposite effects on 217 childhood height and T2D (taller height and lower T2D risk for IGF1; shorter height and 218 higher T2D risk for IGF1R; Supplementary Figure 4). Hence, reported common variant 219 instruments for higher IGF-1 levels comprise a mixture of functionally-opposing signals, i.e. 220 higher levels of bioactive IGF-1 but also higher IGF-1 resistance.

221 Discussion

Here we present the results of an ExWAS to assess the contribution of rare variant burden to T2D risk (Figure 1). We identified three genes previously reported by a recent analysis of the UKBB (GCK, HNF1A, and GIGYF1)¹⁴, provide stronger evidence for a previously nominally associated gene (TNRC6B)¹¹, and identified three new genes (ZEB2, MLXIPL, and IGF1R) where rare variants increase susceptibility to T2D (Figure 2). Using publicly available data,

227 we showed that common variation nearby these genes is associated with a wide range of glycemic and metabolic traits and (Figure 3; Supplementary Table 2)^{2,18}, providing further 228 229 support for these rare variant associations. We further interrogated rare and common variant 230 associations to show that disruption of IGF1R due to damaging missense variants in the 231 cytoplasmic protein kinase domain leads to IGF-1 resistance and higher T2D risk. Overall, 232 our results implicate a wider protective effect of IGF-1 bioactivity on susceptibility to T2D.

While our results are complementary to previous ExWAS^{11,14}, we clarified evidence linking 233 TNRC6B to T2D and identified three additional genes missed by previous analyses of the 234 235 UKBB. A key advantage of our approach was to carefully curate multiple data sources to 236 identify and validate T2D cases. Furthermore, we used a different genetic analytical approach to those previous studies. Nag et al.¹⁴ limited their burden testing to either PTVs, 237 the findings of which we replicate here, or to missense variants with comparatively low 238 deleteriousness scores (REVEL > 0.25 or Missense Tolerance Ratio intragenic percentiles ≤ 239 240 50%). In this study, we have shown the benefit of considering missense variants computationally predicted to be severely damaging (REVEL ≥ 0.5 and 0.7)¹⁵. While such 241 242 variants are much rarer in the population - only ~8% of missense variants in UKBB have 243 REVEL scores ≥ 0.7 – they are much more likely to disrupt protein function and thus 244 increase risk for disease. These conclusions are similar to those shown previously for anthropometric traits¹⁰, which have shown a relationship between PTVs in *IGF1R* and 245 246 several growth measures, but not for damaging missense variants.

247 A key finding of our work is the novel association between *IGF1R* and T2D risk. Loss of 248 function mutations in IGF1R have been reported in children presenting with intra-uterine growth restriction, short stature and elevated IGF-1 levels^{29–31}. Our findings of rare damaging 249 variants at IGF1R, and also at IGFALS and IGFBP3, indicate that reduced IGF-1 bioactivity 250 251 and signalling increases risk for T2D. There are several plausible mechanisms to link IGF1R 252 to T2D. IGF1R, responding to both systemic and locally generated IGF-1, may play a role in the development of several tissues central to the control of glucose metabolism including 253 pancreatic islets, adipose tissue and skeletal muscle³². An alternative explanation involves 254 the complex relationship between growth hormone (GH) and IGF-1. GH, produced in a 255 256 highly controlled and pulsatile manner from the somatotropes of the anterior pituitary, is the 257 major stimulus to the hepatic expression and secretion of IGF-1, the major source of this circulating hormone. GH also has metabolic effects that are independent of IGF-1, largely 258 exerted by its powerful lipolytic effects in adipose tissue^{33–38}, which if uncontrolled can lead 259 260 to the accumulation of ectopic lipid in non-adipose tissue resulting in insulin resistance. This 261 is elegantly demonstrated by studies in mice in which IGF-1 is selectively deleted in the liver^{39,40}. These mice show a striking increase in circulating GH levels, accompanied by 262 marked insulin resistance which is entirely abrogated by the blockade of GH signalling. This 263 264 model can explain the insulin resistance and frequent T2D seen in conditions such as 265 acromegaly, where GH and IGF-1 levels are persistently raised due to a functional 266 somatotrope tumour⁴¹, and the striking protection from T2D seen in patients with Laron 267 Dwarfism, whose markedly reduced circulating IGF-1 levels are due to biallelic LoF mutations in the GH receptor⁴². Loss of function mutations in IGF1R are likely to result in 268 compensatory increases in GH secretion, and consequently higher levels of circulating IGF-1 269 270 that we observed in the carriers of such mutations. While this may partially compensate for 271 impairment in IGF1R function, the IGF1R-independent effects of GH are likely to have a 272 deleterious effect on systemic glucose metabolism. Of note in this regard, a single human 273 proband with a homozygous loss of function mutation in IGF-1 had elevated circulating GH and severe insulin resistance^{43,44}. Therapy with exogenous IGF-1 resulted in suppression of 274

medRxiv preprint doi: https://doi.org/10.1101/2022.03.26.22272972; this version posted March 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

- GH and a dose dependent improvement in insulin sensitivity⁴⁴. Accordingly, genetically 275 reduced GH secretion and signalling would lead to reduced IGF-1 bioactivity, but without the 276 277 consequent effects of elevated GH on fatty acid metabolism and insulin resistance, and 278 hence no alteration in T2D risk. We propose that currently available drugs which reduce GH 279 secretion or block its action may have metabolic benefits in patients with T2D and damaging 280 missense variants in the protein kinase domain of IGF1R.
- 281
- 282 Our findings also demonstrate the challenge of interpreting Mendelian randomisation results 283 of circulating biomarkers. Elevated levels may reflect higher levels of secretion and
- 284 biomarker activity, but are also increased by mechanisms that reduce biomarker
- 285 bioavailability or sensitivity. Hence, genetic instruments for higher biomarker levels may 286 comprise a mixture of markers for both higher and lower biomarker activity. To distinguish 287 these actions, we suggest that individual common variants are first tested for association 288 with some indicator of biomarker activity (i.e. childhood height as an indicator of IGF-1 activity).
- 289 290
- 291 Our rare variant analysis also implicates MLXIPL as a T2D susceptibility gene for the first
- 292 time. MLXIPL encodes the carbohydrate response element binding protein (CHREBP), a transcription factor that acts in concert with its obligate binding partner MLX to regulate the 293 294 cellular response to carbohydrate^{45–47} and is highly expressed in liver, fat, and muscle. 295 Global or tissue-specific ablation of *MLXIPL* in mice impairs insulin sensitivity^{48–51}. Common variants at the MLXIPL locus associate with SHBG, a biomarker of insulin sensitivity⁵² and 296 with serum triglycerides^{53,54}. Notably, *MLXIPL* is one of the 26-28 genes deleted in Williams 297 298 Syndrome, the result of a deletion of contiguous genes on chromosome 7g11.23. Patients
- 299 with this syndrome are characterised by marked insulin resistance and an increased risk of 300 diabetes⁵⁵. It seems likely that haploinsufficiency for *MXLIPL* contributes significantly to the 301 metabolic disturbances characteristic of Williams syndrome.
- 302

303 Overall, our findings suggest that deeper interrogation of multiple variant types when 304 performing ExWAS can and will lead to the discovery of additional genes associated with a 305 wide-range of human diseases.

Methods 306

UK Biobank Data Processing and Quality Control 307

To conduct rare variant burden analyses outlined in this publication, we gueried ES data for 308 454,787 individuals provided by the UKBB study⁵. Individuals were excluded from further 309 310 analysis if they had excess heterozygosity, autosomal variant missingness on genotyping arravs ≥ 5%, or were not included in the subset of phased samples as defined in Bycroft et 311 al.⁵⁶. We further excluded all study participants who were not of broadly European genetic 312 313 ancestry, leaving a total of 421,065 individuals for further analysis. 314

- To perform variant quality control and annotation, we utilised the UKBB Research Analysis 315
- 316 Platform (RAP; https://ukbiobank.dnanexus.com/). The RAP is a cloud-based compute
- 317 environment which provides a central data repository for UKBB ES and phenotypic data.

Using bespoke applets designed for the RAP, we performed additional quality control of ES data beyond that already documented in Backman et al.⁵. Using provided population-level Variant Call Format (VCF) files, we first split and left-corrected multi-allelic variants into

separate alleles using 'bcftools norm'⁵⁷. Next, we performed genotype-level filtering using 321 322 'bcftools filter' separately for Single Nucleotide Variants (SNVs) and Insertions/Deletions 323 (InDels) using a missingness-based approach. With this approach, SNV genotypes with 324 depth < 7 and genotype quality < 20 or InDel genotypes with a depth < 10 and genotype 325 quality < 20 were set to missing (i.e. ./.). We further tested for an expected alternate allele 326 contribution of 50% for heterozygous SNVs using a binomial test; SNV genotypes with a binomial test p. value $\leq 1 \times 10^{-3}$ were set to missing. Following genotype-level filtering we 327 328 recalculated the proportion of individuals with a missing genotype for each variant and 329 filtered all variants with a missingness value > 50%.

330

318

319

320

We next annotated variants using the ENSEMBL Variant Effect Predictor (VEP) v104⁵⁸ with the '--everything' flag and plugins for REVEL¹⁵, CADD⁵⁹, and LOFTEE⁶⁰ enabled. For each

variant, we prioritised a single ENSEMBL transcript based on whether or not the annotated

- transcript was protein-coding, MANE select v0.97, or the VEP Canonical transcript,
- respectively. Individual consequence for each variant was prioritised based on severity as
 defined by VEP. Following annotation, we grouped stop gained, frameshift, splice acceptor.
- defined by VEP. Following annotation, we grouped stop gained, frameshift, splice acceptor,
 and splice donor variants into a single Protein Truncating Variant (PTV) category. Missense
- 338 and synonymous variant consequences are identical to those defined by VEP. Only
- autosomal or chrX variants within ENSEMBL protein-coding transcripts and within transcripts
 included on the UKBB ES assay were retained for subsequent burden testing.

341 Exome-wide association analyses in the UK Biobank

342 To perform rare variant burden tests using filtered and annotated ES data, we employed a 343 custom implementation of BOLT-LMM v2.3.6⁶¹ for the RAP. BOLT-LMM expects two primary inputs: i) a set of genotypes with minor allele count > 100 derived from genotyping arrays to 344 345 construct a null model and ii) a larger set of imputed variants to perform association tests. 346 For the former, we queried genotyping data available on the RAP and restricted to an 347 identical set of individuals used for rare variant association tests. For the latter, and as 348 BOLT-LMM expects imputed genotyping data as input rather than per-gene carrier status, 349 we created dummy genotype files where each variant represents one gene and individuals 350 with a qualifying variant within that gene are coded as heterozygous, regardless of the 351 number of variants that individual has in that gene. To test a range of variant annotation 352 categories across the allele frequency spectrum, we created dummy genotype files for minor 353 allele frequency < 0.1% and singleton high confidence PTVs as defined by LOFTEE, 354 missense variants with REVEL \geq 0.5, missense variants with REVEL \geq 0.7, and synonymous variants. For each phenotype tested, BOLT-LMM was then run with default parameters other 355 356 than the inclusion of the 'ImmInfOnly' flag. When exploring the role of rare variants in the 357 IGF-1/GH axis and to incorporate less deleterious missense variants, we also used an 358 additional set of variant annotations which combined missense variants with CADD ≥ 25 and 359 high confidence PTVs (i.e. Damaging; Supplementary Table 3). To derive association 360 statistics for individual variants, we also provided all 26,657,229 individual markers 361 regardless of filtering status as input to BOLT-LMM. All tested phenotypes were run as continuous traits corrected by age, age², sex, the first ten genetic principal components as 362

medRxiv preprint doi: https://doi.org/10.1101/2022.03.26.22272972; this version posted March 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

calculated in Bycroft et al.⁵⁶, and study participant ES batch as a categorical covariate (either 363 50k, 200k, or 450k). For phenotype definitions used in this study, please refer to 364 365 Supplementary Table 5. Only the first instance (initial visit) was used for generating all phenotype definitions unless specifically noted in Supplementary Table 5. 366

367

To provide an orthogonal approach to validate our BOLT-LMM results, we also performed 368 per-gene burden tests with STAAR¹⁶ and a generalised linear model as implemented in the 369 python package 'statsmodels'⁶². To run STAAR, we created a custom Python and R 370 371 workflow on the RAP. VCF files were first converted into a sparse matrix suitable for use with 372 the R package 'Matrix' using 'bcftools query'. Using the 'STAAR' R package, we first ran a 373 null model with identical coefficients to BOLT-LMM and a sparse relatedness matrix with a relatedness coefficient cutoff of 0.125 as described by Bycroft et al.⁵⁶. We next used the 374 375 function 'STAAR' to test all protein-coding transcripts as outlined above. To run generalised 376 linear models, we used a three step process. First, we ran a null model with all dependent 377 variables as continuous traits, corrected for control covariates identical to those included in 378 BOLT-LMM. Next, using the residuals of this null model, we performed initial regressions on 379 carrier status to obtain a preliminary p. value. Finally, for individual genes that passed a lenient p. value threshold of $<1 \times 10^{-4}$, we recalculated a full model to obtain exact test 380 381 statistics with family set to 'binomial' or 'gaussian' if the trait was binary or continuous, respectively. Generalised linear models utilised identical input to BOLT-LMM converted to a 382

383 sparse matrix.

Common variant GWAS lookups 384

Common variant associations at the identified genes were gueried using the T2D Knowledge 385 Portal (https://t2d.hugeamp.org) and the Open Targets Genetics platform 386 (https://genetics.opentargets.org/)⁶³. Trait associations from the T2D Knowledge Portal are 387 presented in Supplementary Table 2 and were only included if the paired gene was assigned 388 389 as the nearest gene to the association signal as a crude proxy for causality. Accompanying 390 HuGE scores were extracted for the highest-scoring glycaemic common variants associations. Locus2Gene scores based on data from Vujkovic et al.² were extracted from 391 392 the Open Targets Genetics platform and are presented in Supplementary Table 2. For the *IGF1R* locus follow-up, we used sentinel SNP information for Vujkovic et al.² and summary 393 statistics from the recent fasting glucose MAGIC meta-analysis¹⁸ and circulating IGF-1 levels 394 GWAS, eQTL data was accessed through GTEx v8²⁰. Effect estimates in the text have been 395 aligned towards the T2D/glucose increasing alleles, using LD information from LDlink¹⁹. 396 397 Regions in Figure 3 were plotted using LocusZoom⁶⁴.

Mendelian Randomisation Using IGF-1 levels 398

399 To examine the likelihood of a causal effect of IGF-1 on the risk of T2D, we applied 400 Mendelian randomization (MR) analysis. In this approach, genetic variants that are 401 significantly associated with an exposure of interest are used as instrumental variables (IVs) 402 to test the causality of that exposure on the outcome of interest. For a genetic variant to be a 403 reliable instrument, the following assumptions should be met: (1) the genetic instrument is 404 associated with the exposure of interest, (2) the genetic instrument should not be associated 405 with any other competing risk factor that is a confounder, and (3) the genetic instrument

406 should not be associated with the outcome, except via the causal pathway that includes the exposure of interest⁶⁵. As IVs, we used the 831 IGF-1 genome-wide significant signals 407 reported in a recent GWAS on IGF-1²¹. As our outcome data, we selected the largest 408 publicly available independent T2D dataset available in 893,130 European genetic ancestry 409 410 individuals (9% cases) from Mahajan et al.²⁸ If a signal was not present in the outcome GWAS, we searched the UKBB white European dataset for proxies (within 1 Mb and r^2 > 411 0.5) and chose the variant with the highest r^2 value, which left 784 independent markers for 412 413 MR analysis. Genotypes at all variants were aligned to designate the IGF-1-increasing 414 alleles as the effect alleles. 415 To conduct our MR analysis, we used the inverse-variance weighted (IVW) model as the 416 primary model as it offers the most statistical power⁶⁶; however, as it does not correct for 417 heterogeneity in outcome risk estimates between individual variants⁶⁷, we applied a number 418 419 of sensitivity MR methods that better account for heterogeneity⁶⁸. These include an Egger 420 analysis to identify and correct for unbalanced heterogeneity ('horizontal pleiotropy'), indicated by a significant Egger intercept (p<0.05)⁶⁹, and weighted median (WM) and 421 422 penalised weighted median (PWM) models to correct for balanced heterogeneity⁷⁰. In 423 addition, we introduced the radial method to exclude variants from each model in cases 424 where they are recognized as outliers, as well as Steiger filtering to assess for potential 425 reverse causality (i.e. variants with stronger association with the outcome than with the 426 exposure)⁷¹. As previous work on IGF-1 showed a strong association with height, and to a lesser extent BMI²⁷, we also used multivariable MR analysis⁷² to estimate the direct effect of 427 428 IGF-1 levels on T2D not mediated by BMI or height by adjusting for their effects as 429 covariates using queried phenotype data for UKBB participants (Supplementary Table 4; 430 Supplementary Table 5). In order to examine the individual level effect of IGF1 and IGF1R 431 loci on T2D, BMI, childhood and adult height, we performed the variant-specific lookups as well as calculated the Wald ratio using the R package 'TwoSampleMR'⁷³. All results 432 433 presented in the main text are expressed in standard deviations of IGF-1 levels (one S.D. is 434 equivalent to ~5.5 nmol/L in UKBB). Values available in Supplementary Table 4 are raw 435 data, per unit IGF-1.

Acknowledgements 436

437 This work was funded by the Medical Research Council (Unit programs: MC UU 12015/2, MC UU 00006/2, MC UU 12015/1, and MC UU 00006/1). S.L. is supported by a 438 439 Wellcome Trust Clinical PhD Fellowship (225479/Z/22/Z). This research was supported by 440 the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). For the purpose of 441 open access, the author has applied a Creative Commons Attribution (CC BY) licence to any 442 Author Accepted Manuscript version arising. This research was conducted using the UK 443 Biobank Resource under application 9905.

References 444

- 445 1. International Diabetes Federation. IDF Diabetes Atlas, 9th Edition. (International
- Diabetes Federation, 2021). 446

- 447 2. Vujkovic, M. *et al.* Discovery of 318 new risk loci for type 2 diabetes and related
- vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat. Genet.* **52**, 680–691 (2020).
- 450 3. Loos, R. J. F. 15 years of genome-wide association studies and no signs of slowing
 451 down. *Nat. Commun.* **11**, 5900 (2020).
- 452 4. Szustakowski, J. D. *et al.* Advancing human genetics research and drug discovery
- 453 through exome sequencing of the UK Biobank. *Nat. Genet.* **53**, 942–948 (2021).
- 454 5. Backman, J. D. *et al.* Exome sequencing and analysis of 454,787 UK Biobank
- 455 participants. *Nature* **599**, 628–634 (2021).
- 456 6. Fuchsberger, C. *et al.* The genetic architecture of type 2 diabetes. *Nature* 536, 41–47
 457 (2016).
- Flannick, J. *et al.* Exome sequencing of 20,791 cases of type 2 diabetes and 24,440
 controls. *Nature* 570, 71–76 (2019).
- 460 8. Langenberg, C. & Lotta, L. A. Genomic insights into the causes of type 2 diabetes.
 461 *Lancet* **391**, 2463–2474 (2018).
- 462 9. Curtis, D. Analysis of rare coding variants in 200,000 exome-sequenced subjects
- reveals novel genetic risk factors for type 2 diabetes. *Diabetes. Metab. Res. Rev.* 38,
 e3482 (2022).
- 465 10. Wang, Q. *et al.* Rare variant contribution to human disease in 281,104 UK Biobank
 466 exomes. *Nature* **597**, 527–532 (2021).
- 467 11. Deaton, A. M. *et al.* Gene-level analysis of rare variants in 379,066 whole exome
- 468 sequences identifies an association of GIGYF1 loss of function with type 2 diabetes.
- 469 Sci. Rep. **11**, 21565 (2021).
- 470 12. Zhao, Y. *et al.* GIGYF1 loss of function is associated with clonal mosaicism and adverse
 471 metabolic health. *Nat. Commun.* **12**, 4178 (2021).
- 472 13. Jurgens, S. J. et al. Analysis of rare genetic variation underlying cardiometabolic
- diseases and traits among 200,000 individuals in the UK Biobank. *Nat. Genet.* (2022)
- 474 doi:10.1038/s41588-021-01011-w.

- 475 14. Nag, A. *et al.* Human genetic evidence supports MAP3K15 inhibition as a therapeutic
- 476 strategy for diabetes. *Cold Spring Harbor Laboratory* (2021)
- 477 doi:10.1101/2021.11.14.21266328.
- 478 15. Ioannidis, N. M. et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of
- 479 Rare Missense Variants. *Am. J. Hum. Genet.* **99**, 877–885 (2016).
- 480 16. Li, X. *et al.* Dynamic incorporation of multiple in silico functional annotations empowers
- 481 rare variant association analysis of large whole-genome sequencing studies at scale.
- 482 *Nat. Genet.* **52**, 969–983 (2020).
- 483 17. Cummings, B. B. *et al.* Transcript expression-aware annotation improves rare variant
 484 interpretation. *Nature* 581, 452–458 (2020).
- 485 18. Chen, J. *et al.* The trans-ancestral genomic architecture of glycemic traits. *Nat. Genet.*486 53, 840–860 (2021).
- 487 19. Machiela, M. J. & Chanock, S. J. LDlink: a web-based application for exploring
- 488 population-specific haplotype structure and linking correlated alleles of possible

489 functional variants. *Bioinformatics* **31**, 3555–3557 (2015).

- 490 20. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across
 491 human tissues. *Science* 369, 1318–1330 (2020).
- 492 21. Stankovic, S. et al. Elucidating the genetic architecture underlying IGF1 levels and its
- 493 impact on genomic instability and cancer risk. *Wellcome Open Research* (2021)
- 494 doi:10.12688/wellcomeopenres.16417.1.
- 495 22. Favelyukis, S., Till, J. H., Hubbard, S. R. & Miller, W. T. Structure and autoregulation of
 496 the insulin-like growth factor 1 receptor kinase. *Nat. Struct. Biol.* 8, 1058–1063 (2001).
- 497 23. Li, J., Choi, E., Yu, H. & Bai, X.-C. Structural basis of the activation of type 1 insulin-like
 498 growth factor receptor. *Nat. Commun.* **10**, 4567 (2019).
- 499 24. Sandhu, M. S. et al. Circulating concentrations of insulin-like growth factor-I and
- 500 development of glucose intolerance: a prospective observational study. *Lancet* **359**,
- 501 1740–1745 (2002).
- 502 25. Lewitt, M. S. et al. IGF-binding protein 1 and abdominal obesity in the development of

- 503 type 2 diabetes in women. *Eur. J. Endocrinol.* **163**, 233–242 (2010).
- 26. Similä, M. E. *et al.* Insulin-like growth factor I, binding proteins -1 and -3, risk of type 2
- 505 diabetes and macronutrient intakes in men. *Br. J. Nutr.* **121**, 938–944 (2019).
- 506 27. Larsson, S. C., Michaëlsson, K. & Burgess, S. IGF-1 and cardiometabolic diseases: a
- 507 Mendelian randomisation study. *Diabetologia* **63**, 1775–1782 (2020).
- 508 28. Mahajan, A. *et al.* Fine-mapping type 2 diabetes loci to single-variant resolution using
- high-density imputation and islet-specific epigenome maps. *Nat. Genet.* **50**, 1505–1513
 (2018).
- 511 29. Abuzzahab, M. J. *et al.* IGF-I receptor mutations resulting in intrauterine and postnatal
 512 growth retardation. *N. Engl. J. Med.* **349**, 2211–2222 (2003).
- 513 30. Fang, P. *et al.* Severe short stature caused by novel compound heterozygous mutations
- of the insulin-like growth factor 1 receptor (IGF1R). *J. Clin. Endocrinol. Metab.* 97,
 E243–7 (2012).
- 516 31. Inagaki, K. *et al.* A familial insulin-like growth factor-I receptor mutant leads to short
- 517 stature: clinical and biochemical characterization. *J. Clin. Endocrinol. Metab.* 92, 1542–
 518 1548 (2007).
- 32. Rother, K. I. & Accili, D. Role of insulin receptors and IGF receptors in growth and
 development. *Pediatr. Nephrol.* 14, 558–561 (2000).
- 33. Kopchick, J. J., Berryman, D. E., Puri, V., Lee, K. Y. & Jorgensen, J. O. L. The effects of
 growth hormone on adipose tissue: old observations, new mechanisms. *Nat. Rev.*
- 523 *Endocrinol.* **16**, 135–146 (2020).
- 524 34. Arlien-Søborg, M. C. *et al.* Reversible insulin resistance in muscle and fat unrelated to
- 525 the metabolic syndrome in patients with acromegaly. *EBioMedicine* **75**, 103763 (2022).
- 526 35. Nielsen, S., Møller, N., Christiansen, J. S. & Jørgensen, J. O. Pharmacological
- antilipolysis restores insulin sensitivity during growth hormone exposure. *Diabetes* 50,
 2301–2308 (2001).
- 529 36. Høyer, K. L. *et al.* The acute effects of growth hormone in adipose tissue is associated
- 530 with suppression of antilipolytic signals. *Physiol Rep* **8**, e14373 (2020).

- 531 37. Møller, N. *et al.* Effects of a growth hormone pulse on total and forearm substrate fluxes
- 532 in humans. Am. J. Physiol. 258, E86–91 (1990).
- 533 38. Ran, L. et al. Loss of Adipose Growth Hormone Receptor in Mice Enhances Local Fatty
- 534 Acid Trapping and Impairs Brown Adipose Tissue Thermogenesis. *iScience* **16**, 106–
- 535 121 (2019).
- 536 39. Yakar, S. *et al.* Inhibition of growth hormone action improves insulin sensitivity in liver
- 537 IGF-1-deficient mice. J. Clin. Invest. **113**, 96–105 (2004).
- 40. Yakar, S. *et al.* Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. *Diabetes* **50**, 1110–1118 (2001).
- 540 41. Mestron, A. et al. Epidemiology, clinical characteristics, outcome, morbidity and
- 541 mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol 542 de Acromegalia, REA). *Eur. J. Endocrinol.* **151**, 439–446 (2004).
- 543 42. Guevara-Aguirre, J. *et al.* Growth hormone receptor deficiency is associated with a
 544 major reduction in pro-aging signaling, cancer, and diabetes in humans. *Sci. Transl.*
- 545 *Med.* **3**, 70ra13 (2011).
- 43. Woods, K. A., Camacho-Hübner, C., Savage, M. O. & Clark, A. J. Intrauterine growth
- 547 retardation and postnatal growth failure associated with deletion of the insulin-like
- 548 growth factor I gene. *N. Engl. J. Med.* **335**, 1363–1367 (1996).
- 549 44. Woods, K. A. *et al.* Effects of insulin-like growth factor I (IGF-I) therapy on body
- composition and insulin resistance in IGF-I gene deletion. *J. Clin. Endocrinol. Metab.* 85,
 1407–1411 (2000).
- 552 45. Yamashita, H. et al. A glucose-responsive transcription factor that regulates
- 553 carbohydrate metabolism in the liver. *Proc. Natl. Acad. Sci. U. S. A.* 98, 9116–9121
 554 (2001).
- 46. Ma, L., Tsatsos, N. G. & Towle, H. C. Direct role of ChREBP.Mlx in regulating hepatic
 glucose-responsive genes. *J. Biol. Chem.* 280, 12019–12027 (2005).
- 47. Stoeckman, A. K., Ma, L. & Towle, H. C. Mlx is the functional heteromeric partner of the
- 558 carbohydrate response element-binding protein in glucose regulation of lipogenic

- enzyme genes. J. Biol. Chem. 279, 15662–15669 (2004).
- 48. Abdul-Wahed, A., Guilmeau, S. & Postic, C. Sweet Sixteenth for ChREBP: Established
 Roles and Future Goals. *Cell Metab.* 26, 324–341 (2017).
- 562 49. Jois, T. et al. Deletion of hepatic carbohydrate response element binding protein
- 563 (ChREBP) impairs glucose homeostasis and hepatic insulin sensitivity in mice. *Mol*
- 564 *Metab* **6**, 1381–1394 (2017).
- 565 50. Vijayakumar, A. *et al.* Absence of Carbohydrate Response Element Binding Protein in
- 566 Adipocytes Causes Systemic Insulin Resistance and Impairs Glucose Transport. *Cell*
- 567 *Rep.* **21**, 1021–1035 (2017).
- 568 51. lizuka, K., Bruick, R. K., Liang, G., Horton, J. D. & Uyeda, K. Deficiency of carbohydrate
- response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis.
- 570 Proc. Natl. Acad. Sci. U. S. A. **101**, 7281–7286 (2004).
- 571 52. Ruth, K. S. *et al.* Using human genetics to understand the disease impacts of 572 testosterone in men and women. *Nat. Med.* **26**, 252–258 (2020).
- 573 53. Kanai, M. et al. Genetic analysis of quantitative traits in the Japanese population links
- 574 cell types to complex human diseases. *Nat. Genet.* **50**, 390–400 (2018).
- 575 54. Klarin, D. et al. Genetics of blood lipids among ~300,000 multi-ethnic participants of the
- 576 Million Veteran Program. *Nat. Genet.* **50**, 1514–1523 (2018).
- 577 55. Stagi, S. *et al.* Williams-beuren syndrome is a genetic disorder associated with impaired
- 578 glucose tolerance and diabetes in childhood and adolescence: new insights from a
- 579 longitudinal study. *Horm. Res. Paediatr.* **82**, 38–43 (2014).
- 580 56. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
- 581 *Nature* **562**, 203–209 (2018).
- 582 57. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* **10**, (2021).
- 583 58. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).
- 584 59. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting
- the deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* 47,
- 586 D886–D894 (2019).

- 587 60. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in
- 588 141,456 humans. *Nature* **581**, 434–443 (2020).
- 589 61. Loh, P.-R. *et al.* Efficient Bayesian mixed-model analysis increases association power in
- 590 large cohorts. *Nat. Genet.* **47**, 284–290 (2015).
- 591 62. Seabold, S. & Perktold, J. Statsmodels: Econometric and Statistical Modeling with
- 592 Python. Proceedings of the 9th Python in Science Conference (2010)
- 593 doi:10.25080/majora-92bf1922-011.
- 63. Ghoussaini, M. *et al.* Open Targets Genetics: systematic identification of trait-associated
- 595 genes using large-scale genetics and functional genomics. *Nucleic Acids Res.* 49,
- 596 D1311–D1320 (2021).
- 597 64. Boughton, A. P. et al. LocusZoom.js: Interactive and embeddable visualization of
- 598 genetic association study results. *Bioinformatics* (2021)
- 599 doi:10.1093/bioinformatics/btab186.
- 600 65. Smith, G. D. & Ebrahim, S. 'Mendelian randomization': can genetic epidemiology
- 601 contribute to understanding environmental determinants of disease? *Int. J. Epidemiol.*
- 602 **32**, 1–22 (2003).
- 603 66. Slob, E. A. W. & Burgess, S. A comparison of robust Mendelian randomization methods
 604 using summary data. *Genet. Epidemiol.* 44, 313–329 (2020).
- 605 67. Bowden, J. *et al.* A framework for the investigation of pleiotropy in two-sample summary 606 data Mendelian randomization. *Stat. Med.* **36**, 1783–1802 (2017).
- 607 68. Burgess, S., Bowden, J., Fall, T., Ingelsson, E. & Thompson, S. G. Sensitivity Analyses
- 608 for Robust Causal Inference from Mendelian Randomization Analyses with Multiple
- 609 Genetic Variants. *Epidemiology* **28**, 30–42 (2017).
- 610 69. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
- 611 instruments: effect estimation and bias detection through Egger regression. *Int. J.*612 *Epidemiol.* 44, 512–525 (2015).
- 613 70. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in
- 614 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median

- 615 Estimator. *Genet. Epidemiol.* **40**, 304–314 (2016).
- 616 71. Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between
- 617 imprecisely measured traits using GWAS summary data. *PLoS Genet.* **13**, e1007081
- 618 (2017).
- 619 72. Burgess, S. & Thompson, S. G. Multivariable Mendelian randomization: the use of
- 620 pleiotropic genetic variants to estimate causal effects. *Am. J. Epidemiol.* **181**, 251–260
- 621 (2015).
- 622 73. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across
 623 the human phenome. *Elife* **7**, (2018).
- 624